期刊
LEUKEMIA
卷 28, 期 6, 页码 1289-1298出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2013.360
关键词
chronic lymphocytic leukemia; cytoskeleton; migration; drug screening; cytochalasan; microenvironment
资金
- German Jose Carreras Leukemia-foundation [DJCLS R 10/04]
- Helmholtz Virtual Institute
- research project of the German Federal Ministry of Education and Research 'CancerEpiSys'
- Danish Cancer Society [R20-A1157-10-S2]
Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B cells. One of the major challenges in treatment of CLL is the achievement of a complete remission to prevent relapse of disease originating from cells within lymphoid tissues and subsequent chemoresistance. In search for novel drugs that target CLL cells in protective microenvironments, we performed a fungal extract screen using cocultures of primary CLL cells with bone marrow-derived stromal cells. A secondary metabolite produced by Penicillium aquamarinium was identified as Chaetoglobosin A (ChA), a member of the cytochalasan family that showed preferential induction of apoptosis in CLL cells, even under culture conditions that mimic lymphoid tissues. In vitro testing of 89 CLL cases revealed effective targeting of CLL cells by ChA, independent of bad prognosis characteristics, like 17p deletion or TP53 mutation. To provide insight into its mechanism of action, we showed that ChA targets filamentous actin in CLL cells and thereby induces cell-cycle arrest and inhibits membrane ruffling and cell migration. Our data further revealed that ChA prevents CLL cell activation and sensitizes them for treatment with PI3K and BTK inhibitors, suggesting this compound as a novel potential drug for CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据